1University of Colorado Cancer Center.
2Moffitt Cancer Center.
J Natl Compr Canc Netw. 2024 May;22(4):216-225. doi: 10.6004/jnccn.2024.0024.
Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic aims: (1) non-muscle-invasive bladder cancer (NMIBC); (2) muscle invasive, nonmetastatic disease; and (3) metastatic bladder cancer. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guérin (BCG)-unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.
膀胱癌是美国第六大常见癌症，最常见的组织学亚型为尿路上皮癌。膀胱癌的临床谱分为 3 类，其预后、管理和治疗目标不同：（1）非肌肉浸润性膀胱癌（NMIBC）；（2）肌肉浸润性、非转移性疾病；和（3）转移性膀胱癌。这些 NCCN 指南见解详细介绍了 NCCN 膀胱癌指南的最新更新，包括世卫组织第五版《泌尿系统和男性生殖系统肿瘤分类》中的变化，以及 NCCN 指南如何与这些更新保持一致；针对卡介苗（BCG）无应答性非肌肉浸润性膀胱癌的新出现和新兴治疗选择；以及晚期或转移性疾病系统治疗建议的更新。
